BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) an industry leader in oncology testing, announced the commercial launch of an assay for detecting the presence of key tissue markers in prostate cancer, including the methylated version of the GST-Pi gene. LabCorp is the first full-service, national clinical laboratory in the U.S. to launch this assay, the first commercially available methylation assay for prostate cancer. The technology was licensed from Veridex, LLC.
